Integra LifeSciences closed its acquisition of Metasurg's product portfolio.
Here are five things to know about the acquisition:
1. The new products will enhance Integra's lower extremity product offering.
2. Integra LifeSciences revenues were around $6 million in 2013, with double-digit growth over the prior year.
3. Integra LifeScience expects the acquisition to have a minimal impact on the company's 2015 profits and slower growth during the transition period.
4. Long-term, Integra LifeSciences expects to return to double-digit growth.
5. Metasurg is known for several products, including the DigiFuse Cannulated Intramedullary Fusion System. Integra will now also offer Metasurg's BioFix Regenerative Biologics product line.